143 related articles for article (PubMed ID: 3503595)
21. Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-comparison with an osmotic pump tablet and effect of food.
Abrahamsson B; Alpsten M; Bake B; Jonsson UE; Eriksson-Lepkowska M; Larsson A
J Control Release; 1998 Mar; 52(3):301-10. PubMed ID: 9743450
[TBL] [Abstract][Full Text] [Related]
22. New developments in sustained-release antihypertensive therapy: formulation and pharmacokinetic considerations.
Devane JG; Mulligan S; Kavanagh M; Davis SS; Sparrow RA; Wilding IR
Am J Cardiol; 1992 Apr; 69(13):23E-27E. PubMed ID: 1575173
[TBL] [Abstract][Full Text] [Related]
23. [Sandwiched osmotic pump tablet for controlled release of water-insoluble drug].
Liu LX; Khang G; Rhee JM; Lee HB
Yao Xue Xue Bao; 2003 Aug; 38(8):620-3. PubMed ID: 14628456
[TBL] [Abstract][Full Text] [Related]
24. Comparison of nifedipine gastrointestinal therapeutic system and atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris.
Wallace WA; Wellington KL; Chess MA; Liang CS
Am J Cardiol; 1994 Jan; 73(1):23-8. PubMed ID: 8279372
[TBL] [Abstract][Full Text] [Related]
25. Nifedipine GITS (gastrointestinal therapeutic system) bezoar.
Prisant LM; Carr AA; Bottini PB; Kaesemeyer WH
Arch Intern Med; 1991 Sep; 151(9):1868-9. PubMed ID: 1888255
[TBL] [Abstract][Full Text] [Related]
26. Innovative drug delivery systems in cardiovascular medicine: nifedipine-GITS and clonidine-TTS.
Frishman WH; Sherman D; Feinfeld DA
Cardiol Clin; 1987 Nov; 5(4):703-16. PubMed ID: 3331321
[TBL] [Abstract][Full Text] [Related]
27. Once-daily therapy for angina pectoris with nifedipine gastrointestinal therapeutic system. Dosing and clinical efficacy.
Vetrovec GW
Am J Med; 1989 Jan; 86(1A):28-32. PubMed ID: 2644830
[TBL] [Abstract][Full Text] [Related]
28. The kinetics of nifedipine release from porous hydrophilic matrices and the pharmacokinetics in man.
Leucuta SE
Pharmazie; 1988 Dec; 43(12):845-8. PubMed ID: 3247376
[TBL] [Abstract][Full Text] [Related]
29. Once daily nifedipine: the formulation dictates the pharmacokinetic characteristics and the therapeutic responses.
Toal CB; Meredith PA; Elliott HL
Int J Clin Pharmacol Ther; 2012 Mar; 50(3):202-17. PubMed ID: 22373833
[TBL] [Abstract][Full Text] [Related]
30. Dose- and administration time-dependent effects of nifedipine gits on ambulatory blood pressure in hypertensive subjects.
Hermida RC; Calvo C; Ayala DE; López JE; Rodríguez M; Chayán L; Mojón A; Fontao MJ; Fernández JR
Chronobiol Int; 2007; 24(3):471-93. PubMed ID: 17612946
[TBL] [Abstract][Full Text] [Related]
31. Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product.
White WB; Black HR; Weber MA; Elliott WJ; Bryzinski B; Fakouhi TD
Am J Cardiol; 1998 Feb; 81(4):424-31. PubMed ID: 9485131
[TBL] [Abstract][Full Text] [Related]
32. Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.
Murdoch D; Brogden RN
Drugs; 1991 May; 41(5):737-79. PubMed ID: 1712708
[TBL] [Abstract][Full Text] [Related]
33. Relative bioavailability of four controlled-release nifedipine products.
Schall R; Müller FO; Hundt HK; Duursema L; Groenewoud G; Van Dyk M; Van Schalkwyk AM
Biopharm Drug Dispos; 1994 Aug; 15(6):493-503. PubMed ID: 7993987
[TBL] [Abstract][Full Text] [Related]
34. Factors affecting the release of nifedipine from a swellable elementary osmotic pump.
Nokhodchi A; Momin MN; Shokri J; Shahsavari M; Rashidi PA
Drug Deliv; 2008 Jan; 15(1):43-8. PubMed ID: 18197523
[TBL] [Abstract][Full Text] [Related]
35. Therapeutically relevant blood pressure differences with two nifedipine (60 mg) osmotic delivery systems of differing design: three case reports.
Pollak PT
Int J Clin Pharmacol Ther; 2010 Jun; 48(6):400-4. PubMed ID: 20497748
[TBL] [Abstract][Full Text] [Related]
36. GITS--one more dosage form of nifedipine.
Turakhia DP
J Assoc Physicians India; 1990 Jun; 38(6):453-4. PubMed ID: 2384476
[No Abstract] [Full Text] [Related]
37. In vitro and in vivo evaluation of a once-daily controlled-release pseudoephedrine product.
Hwang SS; Gorsline J; Louie J; Dye D; Guinta D; Hamel L
J Clin Pharmacol; 1995 Mar; 35(3):259-67. PubMed ID: 7608314
[TBL] [Abstract][Full Text] [Related]
38. Antihypertensive effectiveness of the nifedipine gastrointestinal therapeutic system.
Gavras I; Mulinari R; Gavras H; Higgins JT; Reeves RL; Zawada ET; Crook J; Halperin AK; Garrett B
Am J Med; 1987 Dec; 83(6B):20-3. PubMed ID: 3332575
[TBL] [Abstract][Full Text] [Related]
39. Trough and peak effects of a single daily dose of nifedipine gastrointestinal therapeutic system (GITS) as assessed by ambulatory blood pressure monitoring. Italian Nifedipine GITS Study Group.
Zanchetti A
J Hypertens Suppl; 1994 Jul; 12(5):S23-7. PubMed ID: 7965282
[TBL] [Abstract][Full Text] [Related]
40. Dissolution and absorption modeling: model expansion to simulate the effects of precipitation, water absorption, longitudinally changing intestinal permeability, and controlled release on drug absorption.
Johnson KC
Drug Dev Ind Pharm; 2003 Sep; 29(8):833-42. PubMed ID: 14570304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
